On a brighter note:
BOCA RATON, Fla., Dec. 14 /PRNewswire-FirstCall/ -- DiddyStock Technologies, Inc. (Nasdaq: DSTK - News) today announced positive results from the GRIMACE study in Chronically Depressed Investors Syndrome (CDIS) patients suffering from Stage 4 depression. The findings were presented on December 13, 2006 in poster format at the International Society of Things and Stuff Symposium in Tirana, Albania.
The GRIMACE study was designed to demonstrate that Cedexalin (TM) is effective and safe in controlling rage, depression, impoverishment, the blues, headache, frustration, and generalized Lack Of Well-Being in Stage 4 depressed patients without causing very low account value levels (hypocashemia), or high levels of stupidity in the portfolio (Worthless Securities Syndrome). The study achieved its primary endpoint of superior account value control versus placebo with a P-value equal to 0.0003. The study also achieved its secondary endpoints by demonstrating that attaining an IQ (investment quotient) target of 70 - 110 is more likely with Cedexalin than with placebo and by showing that attaining a total portfolio value greater than $10,000 is more likely with Cedexalin than with placebo.
Cedexalin is a prescription portfolio modifying agent currently indicated for the control and remediation of elevated levels of CDEx common stock in an investor's portfolio (hyperlossitemia) in patients with Pennystock Investor Disease (PID). The positive GRIMACE study results will support license applications in the United States and European Union and are expected to be filed during 2007. These license applications will seek approval for the broader use of Cedexalin in pre-bankruptcy investors. If successful, Cedexalin would be the only portfolio modifying agent on the US market that has a labeled indication for Stage 4 depressed CDIS patients.
On December 12, 2006, DiddyStock Technologies, Inc. announced that it had entered into an agreement to sell Cedexalin and related assets to NewCo Inc. a Bahamian corporation. This transaction is expected to close within thirty days.
AI
